<?xml version='1.0' encoding='utf-8'?>
<document id="26412032"><sentence text="Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders."><entity charOffset="33-45" id="DDI-PubMed.26412032.s1.e0" text="Paliperidone" /><entity charOffset="50-67" id="DDI-PubMed.26412032.s1.e1" text="Divalproex Sodium" /><pair ddi="false" e1="DDI-PubMed.26412032.s1.e0" e2="DDI-PubMed.26412032.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26412032.s1.e0" e2="DDI-PubMed.26412032.s1.e1" /></sentence><sentence text="The objective of these 2 phase 1, open-label, 2-treatment, single-sequence studies was to evaluate the effect of repeated oral doses of divalproex sodium extended-release (ER) on the pharmacokinetics (PK) of a single dose of paliperidone ER in healthy participants (study 1), and the effect of multiple doses of paliperidone ER on the steady-state PK of valproic acid (VPA) in patients with psychiatric disorders (study 2), respectively"><entity charOffset="136-153" id="DDI-PubMed.26412032.s2.e0" text="divalproex sodium" /><entity charOffset="225-237" id="DDI-PubMed.26412032.s2.e1" text="paliperidone" /><entity charOffset="312-324" id="DDI-PubMed.26412032.s2.e2" text="paliperidone" /><entity charOffset="354-367" id="DDI-PubMed.26412032.s2.e3" text="valproic acid" /><entity charOffset="369-372" id="DDI-PubMed.26412032.s2.e4" text="VPA" /><pair ddi="false" e1="DDI-PubMed.26412032.s2.e0" e2="DDI-PubMed.26412032.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26412032.s2.e0" e2="DDI-PubMed.26412032.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26412032.s2.e0" e2="DDI-PubMed.26412032.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26412032.s2.e0" e2="DDI-PubMed.26412032.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26412032.s2.e0" e2="DDI-PubMed.26412032.s2.e4" /><pair ddi="false" e1="DDI-PubMed.26412032.s2.e1" e2="DDI-PubMed.26412032.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26412032.s2.e1" e2="DDI-PubMed.26412032.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26412032.s2.e1" e2="DDI-PubMed.26412032.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26412032.s2.e1" e2="DDI-PubMed.26412032.s2.e4" /><pair ddi="false" e1="DDI-PubMed.26412032.s2.e2" e2="DDI-PubMed.26412032.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26412032.s2.e2" e2="DDI-PubMed.26412032.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26412032.s2.e2" e2="DDI-PubMed.26412032.s2.e4" /><pair ddi="false" e1="DDI-PubMed.26412032.s2.e3" e2="DDI-PubMed.26412032.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26412032.s2.e3" e2="DDI-PubMed.26412032.s2.e4" /></sentence><sentence text=" In study 1 healthy participants received, in a fixed sequential order, treatment A, paliperidone ER 12 mg (day 1); treatment B, VPA 1000 mg (2 × 500 mg divalproex sodium ER) once daily (days 5 to 18) and paliperidone ER 12 mg (day 15)"><entity charOffset="85-97" id="DDI-PubMed.26412032.s3.e0" text="paliperidone" /><entity charOffset="153-170" id="DDI-PubMed.26412032.s3.e1" text="divalproex sodium" /><entity charOffset="205-217" id="DDI-PubMed.26412032.s3.e2" text="paliperidone" /><entity charOffset="129-140" id="DDI-PubMed.26412032.s3.e3" text="VPA" /><pair ddi="false" e1="DDI-PubMed.26412032.s3.e0" e2="DDI-PubMed.26412032.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26412032.s3.e0" e2="DDI-PubMed.26412032.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26412032.s3.e0" e2="DDI-PubMed.26412032.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26412032.s3.e0" e2="DDI-PubMed.26412032.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26412032.s3.e3" e2="DDI-PubMed.26412032.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26412032.s3.e3" e2="DDI-PubMed.26412032.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26412032.s3.e3" e2="DDI-PubMed.26412032.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26412032.s3.e1" e2="DDI-PubMed.26412032.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26412032.s3.e1" e2="DDI-PubMed.26412032.s3.e2" /></sentence><sentence text=" In study 2 patients received treatment A, VPA (days 1-7); treatment B, VPA + paliperidone ER 12 mg (days 8-12)"><entity charOffset="78-90" id="DDI-PubMed.26412032.s4.e0" text="paliperidone" /><entity charOffset="43-54" id="DDI-PubMed.26412032.s4.e1" text="VPA" /><entity charOffset="72-83" id="DDI-PubMed.26412032.s4.e2" text="VPA" /><pair ddi="false" e1="DDI-PubMed.26412032.s4.e1" e2="DDI-PubMed.26412032.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26412032.s4.e1" e2="DDI-PubMed.26412032.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26412032.s4.e1" e2="DDI-PubMed.26412032.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26412032.s4.e2" e2="DDI-PubMed.26412032.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26412032.s4.e2" e2="DDI-PubMed.26412032.s4.e0" /></sentence><sentence text=" Divalproex sodium ER doses (study 2) were individualized such that systemic therapeutic VPA exposure from prior treatment was maintained on entry into the study"><entity charOffset="1-18" id="DDI-PubMed.26412032.s5.e0" text="Divalproex sodium" /><entity charOffset="89-105" id="DDI-PubMed.26412032.s5.e1" text="VPA" /><pair ddi="false" e1="DDI-PubMed.26412032.s5.e0" e2="DDI-PubMed.26412032.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26412032.s5.e0" e2="DDI-PubMed.26412032.s5.e1" /></sentence><sentence text=" PK assessments were performed at prespecified time points (paliperidone days 1 and 15 [study 1]; VPA days 7 and 12 [study 2])"><entity charOffset="60-72" id="DDI-PubMed.26412032.s6.e0" text="paliperidone" /><entity charOffset="98-109" id="DDI-PubMed.26412032.s6.e1" text="VPA" /><pair ddi="false" e1="DDI-PubMed.26412032.s6.e0" e2="DDI-PubMed.26412032.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26412032.s6.e0" e2="DDI-PubMed.26412032.s6.e1" /></sentence><sentence text=" The oral bioavailability of paliperidone was increased by an estimated 51% (Cmax ) and 51%-52% (AUCs) when coadministered with divalproex sodium ER"><entity charOffset="29-41" id="DDI-PubMed.26412032.s7.e0" text="paliperidone" /><entity charOffset="128-145" id="DDI-PubMed.26412032.s7.e1" text="divalproex sodium" /><pair ddi="false" e1="DDI-PubMed.26412032.s7.e0" e2="DDI-PubMed.26412032.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26412032.s7.e0" e2="DDI-PubMed.26412032.s7.e1" /></sentence><sentence text=" No effect on the steady-state plasma concentration of VPA was observed following repeated coadministration with paliperidone ER: the 90%CI around the VPA exposure ratios for the 2 treatments was within the 80%-125% bioequivalence criteria for Cmax,ss and AUCτ "><entity charOffset="55-58" id="DDI-PubMed.26412032.s8.e0" text="VPA" /><entity charOffset="113-125" id="DDI-PubMed.26412032.s8.e1" text="paliperidone" /><entity charOffset="151-162" id="DDI-PubMed.26412032.s8.e2" text="VPA" /><pair ddi="false" e1="DDI-PubMed.26412032.s8.e0" e2="DDI-PubMed.26412032.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26412032.s8.e0" e2="DDI-PubMed.26412032.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26412032.s8.e0" e2="DDI-PubMed.26412032.s8.e2" /><pair ddi="false" e1="DDI-PubMed.26412032.s8.e1" e2="DDI-PubMed.26412032.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26412032.s8.e1" e2="DDI-PubMed.26412032.s8.e2" /></sentence><sentence text=" Both VPA and paliperidone ER were well tolerated, and no new safety concerns were identified"><entity charOffset="6-9" id="DDI-PubMed.26412032.s9.e0" text="VPA" /><entity charOffset="14-26" id="DDI-PubMed.26412032.s9.e1" text="paliperidone" /><pair ddi="false" e1="DDI-PubMed.26412032.s9.e0" e2="DDI-PubMed.26412032.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26412032.s9.e0" e2="DDI-PubMed.26412032.s9.e1" /></sentence><sentence text="" /></document>